Literature DB >> 17616810

The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome.

Mohamed Salhab1, Wen G Jiang, Robert F Newbold, Kefah Mokbel.   

Abstract

BACKGROUND: Telomerase is a ribonucleoprotein enzyme that synthesises telomeres in human germ cells, embryogenesis and in cancer, maintaining chromosomal length, stability and cellular immortality. The hTERT gene is the rate-limiting determinant of telomerase reactivation during immortalization and malignant transformation. Telomeric DNA-binding proteins have been attracting increasing interest due to their essential role in the regulation of telomeric DNA length and in protecting against chromosomal end-to-end fusion. These proteins include hTR, TRF1, TRF2, TANK1, TANK2, POT1, TIN2, EST1, and TEP. This study represents the first comprehensive investigation of the mRNA expression of key telomere-related genes in human breast cancer.
METHODS: One hundred and twenty seven tumour tissues and 33 normal tissues were analyzed. Levels of transcription of hTERT, hTR, TRF1, TRF2, TANK1, TANK2, POT1, TIN2, EST1, and TEP1 were determined using real-time quantitative PCR. The mRNA expression of these genes was normalized against CK19 and was then analyzed against the pathological parameters and clinical outcome over a 10 year follow up period.
RESULTS: The mRNA expressions of hTERT, hTR, TANK1, EST1, and TEP1 were higher in tumour samples compared with normal breast tissue. This reached statistical significance for EST1 when comparing good prognosis tumours with normal breast tissue (means=11013 vs 1160, P=0.05). Both hTERT and TEP1 levels significantly predicted overall survival (P=0.012 and 0.005 respectively) and disease-free survival (P=0.0011 and 0.01 respectively). The mRNA levels of TANK2 and POT1 were lower in malignant tissues compared with non-malignant breast tissues and this difference reached statistical significance when comparing the levels in normal tissues with those in advanced tumours (P=0.0008 and P=0.038 respectively). Their levels fell further with increasing tumour's stage and were higher in tumours from patients who remained disease free compared with those who developed local recurrence or distant metastasis or died from breast cancer.TRF2 showed a trend similar to that of TANK2 and POT1. Furthermore, there was a highly significant correlation between TANK1 expression and that of hTERT, hTR, TRF1, TRF2 and EST1, (r=0.533, 0.586, 0.608, 0.644 and 0.551 respectively, P<0.001).
CONCLUSIONS: Genes encoding telomere-associated proteins display different patterns of mRNA expression in human breast cancer, and in normal breast tissue, suggesting different and sometimes opposing roles in mammary carcinogenesis. hTERT, hTR, TANK1, EST1 and TEP1 seem to be up-regulated, with hTERT and TEP1 correlating with clinical outcome. Conversely, TANK2 and POT1 transcription levels demonstrate a compelling trend to be lower in malignant tissues and lower still in those patients who develop recurrent disease suggesting that TANK2 and POT1 may act as tumour suppressor genes possibly by negatively regulating telomerase activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616810     DOI: 10.1007/s10549-007-9622-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

1.  Elevated TRF2 in advanced breast cancers with short telomeres.

Authors:  Malissa C Diehl; Michael O Idowu; Katherine N Kimmelshue; Timothy P York; Colleen K Jackson-Cook; Kristi C Turner; Shawn E Holt; Lynne W Elmore
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

2.  Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.

Authors:  Andrew J Pellatt; Roger K Wolff; Gabriela Torres-Mejia; Esther M John; Jennifer S Herrick; Abbie Lundgreen; Kathy B Baumgartner; Anna R Giuliano; Lisa M Hines; Laura Fejerman; Richard Cawthon; Martha L Slattery
Journal:  Genes Chromosomes Cancer       Date:  2013-04-30       Impact factor: 5.006

3.  Expression of Telomere Binding Proteins (RAP1 and POT1) in Renal Cell Carcinoma and Their Correlation with Clinicopathological Parameters.

Authors:  Deeksha Pal; Shrawan Kumar Singh; Nandita Kakkar; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2016-09-03

4.  Reduced expression of TRF1 is associated with tumor progression and poor prognosis in oral squamous cell carcinoma.

Authors:  Hui-Ching Chuang; Chang-Han Chen; Chao-Cheng Huang; Fu-Min Fang; Hsin-Ting Tsai; Chih-Yen Chien
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

5.  Two genetic variants in telomerase-associated protein 1 are associated with stomach cancer risk.

Authors:  Dong-Hao Jin; Sung Kim; Duk-Hwan Kim; Joobae Park
Journal:  J Hum Genet       Date:  2016-06-16       Impact factor: 3.172

6.  High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis.

Authors:  Angela Ying-Jian Li; Her Helen Lin; Ching-Ying Kuo; Hsiu-Ming Shih; Clay Chia Chun Wang; Yun Yen; David Kong Ann
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

7.  Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival.

Authors:  Jing Shen; Marilie D Gammon; Mary Beth Terry; Patrick T Bradshaw; Qiao Wang; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  Breast Cancer Res Treat       Date:  2012-04-12       Impact factor: 4.872

8.  Gene expression levels of human shelterin complex and shelterin-associated factors regulated by the topoisomerase II inhibitors doxorubicin and etoposide in human cultured cells.

Authors:  Masahiro Kato; Masahiro Nakayama; Minako Agata; Kenichi Yoshida
Journal:  Tumour Biol       Date:  2012-12-18

9.  Molecular characterisation of breast cancer patients at high and low recurrence risk.

Authors:  Serena Bonin; Davide Brunetti; Elena Benedetti; Isabella Dotti; Nader Gorji; Giorgio Stanta
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

10.  Keeping those telomeres short! an innovative intratumoral long-term drug delivery system.

Authors:  B H Laster; C Isaacson; E Perets; M Msamra; E Priel; J Kalef-Ezra; J Kost
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-30       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.